CINECA IRIS Institutional Research Information System

ELISEI, ROSSELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.054
EU - Europa 14.347
AS - Asia 6.210
AF - Africa 620
SA - Sud America 154
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 14
Totale 47.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.464
IT - Italia 4.139
CN - Cina 3.326
DE - Germania 3.238
SE - Svezia 2.836
SG - Singapore 1.291
BG - Bulgaria 1.145
GB - Regno Unito 889
TR - Turchia 634
CA - Canada 564
AT - Austria 484
VN - Vietnam 415
CI - Costa d'Avorio 386
UA - Ucraina 380
FI - Finlandia 363
RU - Federazione Russa 337
IN - India 201
SN - Senegal 185
HK - Hong Kong 144
CH - Svizzera 133
BR - Brasile 105
BE - Belgio 85
NL - Olanda 74
FR - Francia 57
CZ - Repubblica Ceca 38
IR - Iran 37
JP - Giappone 35
PL - Polonia 29
GR - Grecia 26
KR - Corea 25
AU - Australia 21
ID - Indonesia 16
CL - Cile 15
MX - Messico 14
ES - Italia 13
EU - Europa 13
IE - Irlanda 13
IL - Israele 13
RO - Romania 12
TW - Taiwan 11
HU - Ungheria 10
NG - Nigeria 10
PK - Pakistan 10
BJ - Benin 9
LT - Lituania 9
RS - Serbia 9
AR - Argentina 7
MA - Marocco 7
SK - Slovacchia (Repubblica Slovacca) 7
CR - Costa Rica 6
PH - Filippine 6
BY - Bielorussia 5
CO - Colombia 5
CY - Cipro 5
DK - Danimarca 5
EC - Ecuador 5
MG - Madagascar 5
MY - Malesia 5
PE - Perù 5
VE - Venezuela 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
BD - Bangladesh 4
EG - Egitto 4
NZ - Nuova Zelanda 4
SA - Arabia Saudita 4
SV - El Salvador 4
BO - Bolivia 3
EE - Estonia 3
GE - Georgia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
DZ - Algeria 2
IQ - Iraq 2
IS - Islanda 2
JO - Giordania 2
LK - Sri Lanka 2
MN - Mongolia 2
NO - Norvegia 2
PY - Paraguay 2
TN - Tunisia 2
UY - Uruguay 2
A1 - Anonimo 1
AL - Albania 1
AO - Angola 1
GT - Guatemala 1
HR - Croazia 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MT - Malta 1
MU - Mauritius 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
Totale 47.423
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.865
Fairfield 2.812
Chandler 2.124
Ann Arbor 1.965
Houston 1.872
Santa Clara 1.730
Ashburn 1.573
Seattle 1.220
Sofia 1.142
Shanghai 1.062
Wilmington 1.037
Milan 1.013
Cambridge 967
New York 748
Beijing 703
Singapore 690
Boardman 538
Princeton 521
Ottawa 516
Vienna 456
Lawrence 444
Jacksonville 434
Abidjan 386
Medford 360
Izmir 349
Serra 327
Des Moines 278
Nanjing 266
Florence 232
Pisa 229
London 222
Istanbul 211
Dearborn 190
Dong Ket 187
Dakar 185
Rome 169
San Diego 165
Frankfurt am Main 158
Boulder 133
Hong Kong 122
Bern 120
Bremen 119
Redwood City 107
Nanchang 99
Munich 96
Ogden 90
Fuzhou 84
Brussels 80
Jüchen 74
Kunming 73
Washington 72
Los Angeles 65
Tianjin 62
Changsha 61
Düsseldorf 59
Lancaster 57
Shenyang 55
Kocaeli 54
Hebei 53
Helsinki 53
Nürnberg 52
Quanzhou 51
Redmond 51
Jiaxing 50
Norwalk 48
Dallas 47
Naples 47
Guangzhou 40
Chicago 39
Hefei 38
Zhengzhou 37
Falls Church 36
Hangzhou 36
Detroit 32
Wuhan 30
Bologna 29
Jinan 29
Phoenix 28
Grafing 27
Pune 27
Brno 26
Toronto 25
Vicopisano 25
Chengdu 24
Lucca 23
Hyderabad 21
Verona 21
Genoa 20
Sacile 19
Auburn Hills 18
Parma 18
Xiamen 18
Cascina 16
Indiana 16
Orange 16
Palermo 16
Tokyo 16
Turin 16
Marseille 15
Napoli 15
Totale 33.292
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 897
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 275
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 270
null 259
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 204
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 203
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 201
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 199
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 197
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 years follow up study 194
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 186
T cell responses to orbital antigens in thyroid-associated ophthalmopathy. 185
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 184
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 180
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 174
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 174
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 173
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 172
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 171
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 171
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 171
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 171
Circulating neuron-specific enolase in medullary thyroid cancer. 169
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 167
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 167
Thyroid carcinoma in thyrotoxic patients treated by surgery. 166
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 164
Targeted Therapy in Thyroid Cancer: State of the Art 163
Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. 161
null 160
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 160
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 160
Routine serum calcitonin measurement in the evaluation of thyroid nodules 159
Advances in the follow-up of differentiated or medullary thyroid cancer. 159
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 158
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 158
Identification of two distinct molecular subtypes by digital RNA counting of "non-invasive follicular tumour with papillary-like nuclear features (NIFTP)" 158
null 157
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 157
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 155
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 154
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 154
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 153
Thyroid cancer in children and adolescents. 151
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium 151
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 150
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 150
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 150
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 149
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 149
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 149
Motesanib diphosphate in progressive differentiated thyroid cancer 148
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 148
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 148
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 147
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 147
RET point mutations in Thyroid Carcinoma 146
null 146
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. 145
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 145
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 145
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 145
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 145
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 144
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 142
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 141
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 141
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 139
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 138
Genome-wide association study on differentiated thyroid cancer. 138
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 138
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 138
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 137
null 137
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 136
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 136
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 135
Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes 134
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 134
Inherited variants in genes somatically mutated in thyroid cancer 134
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 133
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 133
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 133
Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. 132
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 131
Il carcinoma tiroideo: nuove prospettive terapeutiche. 131
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 131
Post-surgical follow-up of differentiated thyroid cancer. 130
Thyroid consequences of the Chernobyl nuclear accident. 130
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 130
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 129
Anaplastic thyroid cancer therapy: dream or reality? 129
Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer 129
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 129
Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. 128
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 128
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 128
Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice 128
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 127
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 127
Totale 16.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.151
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.151
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.028 0 0 0 0 0 0 904 637 773 647 899 168
2020/20213.691 386 244 314 147 292 247 281 320 340 316 244 560
2021/20225.321 124 233 126 379 1.098 697 178 241 285 218 339 1.403
2022/20237.689 971 1.124 611 611 766 910 137 614 1.324 73 456 92
2023/20245.346 584 554 636 381 711 926 288 173 141 115 263 574
2024/20255.746 170 661 234 992 1.595 1.508 586 0 0 0 0 0
Totale 48.384